Plain-English translation of NCT05538091 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications called and in people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has become resistant to standard platinum chemotherapy. The theory is that these medications work together in a new way: one medication helps block a signaling pathway in cancer cells, while the other helps your immune system recognize and fight the cancer. Researchers hope this combination may help people whose cancers have stopped responding to earlier treatments.
Advanced ovarian cancers often come back and eventually become resistant to standard treatments, leading to poor outcomes. This trial exists because current options are limited for people whose cancer no longer responds to platinum chemotherapy, and researchers believe that combining these two medications in a new way might offer a better chance of slowing or stopping cancer growth.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will take as a daily oral pill (150 mg each day) and receive as an intravenous infusion every 3 weeks. You will have regular clinic visits for treatment administration and monitoring, including blood tests and imaging scans to see how your cancer is responding. The trial is designed to involve about 48 participants total, and your doctor will follow you closely throughout the study to watch for side effects and track your progress.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
United States